Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

  title={Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.},
  author={Margaret M. Centenera and Joanna L. Gillis and Adrienne R. Hanson and Shalini Jindal and Renea A Taylor and Gail P Risbridger and Peter D. Sutherland and Howard I. Scher and Ganesh V. Raj and Karen E. Knudsen and Trina M Yeadon and Wayne D Tilley and Lisa M Butler},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={18 13},
PURPOSE Targeting Hsp90 has significant potential as a treatment for prostate cancer, but prototypical agents such as 17-allylamino-17 demethoxygeldanamycin (17-AAG) have been ineffective in clinical trials. Recently, a phase I study aimed at defining a biologically active dose reported the first response to an Hsp90 inhibitor in a patient with prostate cancer, which supports the development of new generation compounds for this disease. EXPERIMENTAL DESIGN The biological actions of two new… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
31 Extracted Citations
29 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 31 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 29 references

A phase I studyof the heat shockprotein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumors

  • S Pacey, RH Wilson, WaltonMI, EatockM, A Hardcastle, A Zetterlund
  • Clin Cancer Res
  • 2011

AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies

  • TA Samuel, C Sessa, C Britten, KS Milligan, MM Mita, U Banerji
  • ASCO Meeting Abstracts
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…